Testimony Before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee Regarding Aducanumab for Treatment of Alzheimer’s Disease

View complete testimony as PDF

View PowerPoint slides as PDF

View Press Statement

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Peripheral and Central Nervous System Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve aducanumab for treatment of Alzheimer’s disease because there is not substantial evidence of effectiveness.

See Public Citizen’s other work on aducanumab.